- Report
- June 2025
- 150 Pages
Global
From €2444EUR$2,699USD£2,085GBP
- Report
- March 2023
- 147 Pages
Global
From €4481EUR$4,949USD£3,823GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4482EUR$4,950USD£3,823GBP
- Report
- May 2024
- 133 Pages
Global
From €2716EUR$2,999USD£2,316GBP
€3621EUR$3,999USD£3,089GBP
- Report
- April 2023
- 115 Pages
Global
From €4301EUR$4,750USD£3,669GBP
- Report
- April 2023
- 117 Pages
Global
From €4301EUR$4,750USD£3,669GBP
- Report
- September 2024
- 128 Pages
Global
From €13578EUR$14,995USD£11,582GBP
- Report
- April 2025
- 133 Pages
Global
From €16294EUR$17,995USD£13,899GBP
- Report
- August 2024
- 49 Pages
Global
From €3617EUR$3,995USD£3,086GBP
- Clinical Trials
- December 2023
- 2092 Pages
Global
From €2264EUR$2,500USD£1,931GBP
- Report
- January 2023
- 90 Pages
Global
From €3165EUR$3,495USD£2,700GBP
- Report
- April 2025
- 150 Pages
Global
From €4392EUR$4,850USD£3,746GBP
- Report
- January 2024
- 150 Pages
Global
From €4392EUR$4,850USD£3,746GBP
- Report
- July 2025
- 100 Pages
Global
From €3500EUR$4,141USD£3,090GBP
- Report
- April 2025
- 21 Pages
Global
From €16294EUR$17,995USD£13,899GBP
- Report
- May 2023
- 109 Pages
Global
From €3500EUR$4,141USD£3,090GBP
- Report
- May 2023
- 79 Pages
Global
From €3500EUR$4,141USD£3,090GBP
- Report
- January 2025
- 132 Pages
Global
From €860EUR$950USD£734GBP
- Report
- January 2025
- 132 Pages
Global
From €860EUR$950USD£734GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more